Cronos Group (CRON) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Cronos Group published the results on November 5, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Revenue on this page is Cronos Group's net revenue, after excise taxes. Net revenue before excise taxes was $83.9 million in Q3 2026, with $20.5 million of excise taxes deducted.
• Cronos Group reports in U.S. dollars and has one reportable segment. Net income shown is the amount attributable to Cronos Group, after $4.0 million attributable to the non-controlling interest in Cronos GrowCo.
• Cronos Group completed its acquisition of CanAdelaar B.V., an operator in the Netherlands' adult-use cannabis pilot program, on October 15, 2026, after the quarter ended.

Source: Cronos Group Q3 2026 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Cronos Group splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Cronos Group's Canada revenue was $35.1 million in Q3 2026, up 52% from $23.1 million in Q3 2025, 55% of total revenue.
• Cronos Group's Israel revenue was $15.1 million in Q3 2026, up 33% from $11.4 million in Q3 2025, 24% of total revenue.
• Cronos Group's Other countries revenue was $13.2 million in Q3 2026, up 614% from $1.9 million in Q3 2025, 21% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Net revenue (after excise taxes) and diluted EPS attributable to Cronos Group, each as first reported in that quarter's release. The Q4 2025 release printed diluted EPS as a dash, which is shown here as $0.00.

We do not hold a confirmed date for Cronos Group's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 5, 2026

Cronos Group reported Q3 2026 net revenue of $63.5 million, up 75% from $36.3 million. Cannabis flower made up $48.0 million of it, against $26.4 million a year earlier, and cannabis extracts $15.5 million, against $10.0 million. (Cronos Group Q3 2026 release, Nov 5, 2026; Cronos Group Form 10-Q, Q3 2026, Nov 5, 2026)

By customer location, Canada brought in $35.1 million (from $23.1 million), Israel $15.1 million (from $11.4 million) and other countries $13.2 million (from $1.9 million). Cronos attributed the increase to higher flower sales in Israel and other countries, Germany in particular, which carry no excise taxes, higher flower and extract sales in Canada, and a stronger New Israeli Shekel against the U.S. dollar. (Cronos Group Form 10-Q, Q3 2026, Nov 5, 2026; Cronos Group Q3 2026 release, Nov 5, 2026)

Cronos Israel's net revenue rose 33% year over year, or 19% on a constant-currency basis, its eleventh consecutive record quarter. International revenue outside Israel rose 614%, led by flower demand in Germany. In Canada the Spinach brand was the #2 cannabis brand with 6.3% national share, the #1 edibles brand with 21.8% share and the #1 vape brand with 11.4% share, per Hifyre Retail Analytics data cited in the release. (Cronos Group Q3 2026 release, Nov 5, 2026)

Sales are concentrated among a few buyers. In Q3 2026 three major customers together accounted for 52% of net revenue before excise taxes ($43.8 million), against two customers and 46% a year earlier. (Cronos Group Form 10-Q, Q3 2026, Nov 5, 2026)

Excise taxes take a large share of Canadian sales: Cronos reported $83.9 million of net revenue before excise taxes and $20.5 million of excise taxes in the quarter. In Israel Israeli authorities have investigated alleged dumping of Canadian medical cannabis imports; the Trade Levies Commissioner proposed a 175% duty in November 2024, and the 10-Q says it remains uncertain whether a duty will be imposed. (Cronos Group Q3 2026 release, Nov 5, 2026; Cronos Group Form 10-Q, Q3 2026, Nov 5, 2026)

Cronos Group earned $0.04 per diluted share in Q3 2026, down from $0.07, even though operating income swung to $9.0 million from a $0.5 million loss. The year-ago quarter carried a $19.8 million foreign currency gain, against a $0.2 million loss this year, and Cronos recorded an income tax provision of $0.9 million against a $1.3 million benefit. (Cronos Group Q3 2026 release, Nov 5, 2026)

Much of Cronos's profit still comes from its cash pile. Interest income, net was $9.2 million in the quarter, against $11.7 million a year earlier, on cash, short-term investments and interest-bearing deposits of $840.6 million. Cronos does not report an adjusted EPS; its Adjusted EBITDA was $17.1 million, up from $5.7 million, and excludes interest income, share-based compensation ($2.3 million), revaluation gains and other items. (Cronos Group Q3 2026 release, Nov 5, 2026)

Net income attributable to Cronos Group was $13.8 million after $4.0 million attributable to the non-controlling interest in Cronos GrowCo. Cronos repurchased 3.2 million shares for $9.4 million in Q3 2026 and 15.5 million shares for $42.3 million over nine months, retiring them; its current program, authorized May 8, 2026, allows up to $50 million through May 13, 2027. Altria owned approximately 41.0% of Cronos's shares at the end of 2025. (Cronos Group Q3 2026 release, Nov 5, 2026; Cronos Group Form 10-Q, Q3 2026, Nov 5, 2026; Cronos Group Form 10-K, 2025, Feb 26, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Cronos Group does not publish a revenue or earnings outlook in its release. The Q3 2026 release points instead to the October 15, 2026 closing of the CanAdelaar acquisition in the Netherlands and to continued buybacks under its repurchase program. (Cronos Group Q3 2026 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Cronos Group, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Cronos Group's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning CRON is on is CRON a buy or a sell?, what analysts expect next is on the CRON forecast, and what the company does is on the Cronos Group (CRON) stock page.

Every number on this page can be traced to a document Cronos Group published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.